The case for & against
Bull & Bear analysis
Bearish
DocGo, Inc. (NASDAQ: DCGO) is a leading provider of mobile healthcare services and telehealth solutions, specializing in integrated virtual care. The company has positioned itself as a key player in the healthcare sector, particularly in response to the rising demand for more accessible and efficient healthcare solutions. Through its offerings, which include medical transportation and mobile phlebotomy services, DocGo aims to bridge the gap in care and provide effective responses to the growing healthcare needs of its patient base, especially in the context of chronic disease management and preventative care.
Bull says
- ↑Q1 2026 revenue $75.6M, +24% YoY ex-migrant services
- ↑SteadyMD integration added $9M to Q1 2026 revenue
- ↑2026 revenue guidance raised to $300–315M on strong demand
- ↑Generated $33.6M operating cash flow in Q2 2025
- ↑Mobile phlebotomy segment set for ~75% growth in visits
- ↑Strong liquidity, moderate leverage and 0.1880% dividend yield
Bear says
- ↓Q1 2026 adjusted EBITDA loss $10.2M vs $3.9M year-ago
- ↓Deeply negative momentum and high stock volatility signal risk
- ↓Loss of migrant contracts cut revenue from $96M to $75.6M
- ↓Cash fell from $68.3M to $59.9M as receivables delayed
- ↓Negative earnings yield and weak profitability factors persist
- ↓Large-investor skepticism reflected in continued size pressure
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-13-2026neutral
Transcript signals
Bull points
- We reported a strong top line of $75.6 million in revenue during the first quarter with an adjusted EBITDA loss of $10.2 million.
- Additionally, we increased our 2026 revenue guidance from a range of $290 to $310 million to $300 to $315 million while leaving our 2026 adjusted EBITDA guidance unchanged at a loss of $5 to $10 million.
- First, a major driver of our strong revenue performance and increased revenue guidance is our virtual care offering, SteadyMD, which generated in excess of $9 million in revenue beating the previous high set in the fourth quarter of last year by roughly $1 million and completed approximately 1.1 million total visits and lab orders during the period, up 38% when compared to last year.
Bear points
- We experienced labor inefficiencies as a result of SteadyMD's exceptional growth, which negatively impacted our consolidated gross margin by approximately 60 basis points.
- In addition, we saw a significant increase in fuel costs in March driven by the war in the Middle East. We estimate that every $1 increase at the pump cost us about 35 basis points of consolidated gross margin, and average fuel costs in Q2 to date have remained at this elevated level, which we expect to be a continued drag on gross margin over the near term.
- Total revenue for the first quarter of 2026 was $75.6 million compared to $96 million in the first quarter of 2025.
Read full transcript analysis ›